NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy.

Area of Science:

• Immunology
• Oncology
• Genetics

Background:

• Checkpoint blockade immunotherapy shows promise for various cancers.
• Cancer cells can evade immune detection, limiting immunotherapy effectiveness.
• Identifying suitable patients is vital due to treatment costs and side effects.

Purpose of the Study:

• To investigate NLRC5 as a predictive biomarker for checkpoint blockade immunotherapy response.
• To evaluate NLRC5 expression in relation to anti-CTLA-4 and anti-PD1 therapies in melanoma.

Main Methods:

• Analysis of NLRC5 and MHC class I gene expression in melanoma tumors from immunotherapy responders and non-responders.
• Multivariate analysis incorporating tumor mutation number, neo-antigen load, and PD-L2 expression.
• Correlation of NLRC5 expression/methylation and mutation load with patient survival.

Main Results:

• Melanoma patients responding to immunotherapy had higher NLRC5 and MHC class I gene expression.
• Multivariate analysis improved stratification of responders versus non-responders to anti-CTLA-4 therapy.
• NLRC5 expression and tumor mutation load significantly correlated with increased patient survival.

Conclusions:

• NLRC5 tumor expression is a potential predictive biomarker for anti-CTLA-4 and anti-PD1 immunotherapy response in melanoma.
• Combined assessment of NLRC5 and tumor mutation load may offer valuable prognostic insights.
• These findings could guide patient selection for immunotherapy, optimizing treatment efficacy and resource allocation.